Commentary & Perspectives

Earlier Detection of Organ Rejection

CAP review outlines how donor-derived DNA assays can support earlier, less invasive detection of graft injury

  • By

  • February 27, 2026

  • 2 min

Share

Donor-derived cell-free DNA (dd-cfDNA) testing is revolutionizing the monitoring of solid organ transplants by enabling earlier detection of graft injuries such as acute rejection. Following transplantation, fragments of donor DNA can be quantified in a recipient's bloodstream, with low levels indicating stable graft health. The review highlights two main detection methods: next-generation sequencing and droplet digital PCR, with applications particularly in kidney and heart transplants. This testing enhances clinical decision-making by potentially reducing unnecessary biopsies and improving personalized care.

Original Source(s)

Earlier Detection of Organ Rejection

CAP review outlines how donor-derived DNA assays can support earlier, less invasive detection of graft injury

  • February 27, 2026

  • 2 min

Related Content

Unexpected Diagnosis in Ring Finger Mass

Histopathology reveals digital actinomycosis in a young patient.

What Shapes Pediatric Platelet Response?

REDS-IV-P data examine how storage time, pathogen reduction, and donor factors affect transfusion outcomes in pediatric patients

From Genome to Multi-ome

Why scientists should rethink rare disease investigation methods